Value in Health

Article	Citations
HPR6 Beyond Conventional Clinical Value: Estimating the Impact of Accelerated Approvals on Therapeutic Bridging between Innovative Therapies	500
PNS48 Do US Commercial Health Plans Cite ICER Reports in Their Specialty Drug Coverage Policies? an Empirical Analysis	472
Editorial Board	92
HPR25 Patient Organisations' Submissions to the Pharmaceutical Pricing Board in Finland	81
Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare	74
Table of Contents	72
Editorial Board	69
HTA33 Does the Selection of Participating Regions Impact the Outcome of Spanish Therapeutic Positioning Reports?	66
Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact	66
MSR47 Feasibility Assessment of Indirect Treatment Comparison of Biologics for Treating Chronic Rhinosinusitis with Nasal Polyps	57
EE158 Budget Impact of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder from a US Payer Perspective	56
HTA46 Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany	54
HSD35 If Primary Prevention Is the Solution, Why Don't We Take Advantage of All Opportunities in Brazil?	53
EE257 Cost-Effectiveness Analysis of AI-Assisted Radiological Assessment in Patients With Relapsing Remitting Multiple Sclerosis in the UK	51
POSB179 Epidemiological Disease Burden of Heart Failure, Unspecified Based on Routinely Collected Health Insurance Claims Data	48
HPR146 Specialty Pharmacy Use and Adherence to Oral Anticancer Medications for Breast Cancer and Prostate Cancer: Implications for Medicare Part D Policy	47
POSC176 Is Pain Severity Associated with Functional Limitations Among United States Adults? A Cross-Sectional Study Using 2018 Medical Expenditure Panel Survey	45
HTA109 Diagnostic Accuracy of 0.3T MRI for Knee Injuries- A Systematic Review	43
EE237 The Risk-Based Price: Incorporating Uncertainty and Risk Attitues in Health Technology Pricing	43
POSC173 The Association Between Physical Activity, Body Mass Index and Health Complaints Among Hungarian School-Aged Children	43
PCR11 Understanding the Patient Experience of Erythropoietic Protoporphyria and X-Linked Protoporphyria: A Qualitative Study	42
POSB213 Assessing the Changes of Hungarian Health Professional Workforce, Proportional to Population between 2003-2018	39
HTA47 Definition of a System of Factors to Improve the Quality of Decision-Making Process in Health Technology Assessment	39
MSR93 A Systematic Review of Current Evidence and Gaps on the Impact of Oral Antipsychotic Treatments in Schizophrenia	39
SA60 Seeking ISPOR Abstracts: Is Searching Embase Enough?	38

PCR68 Patient-Provider Communication and Health-Related Quality of Life Among Individuals with Chronic Obstructive Pulmonary Disease in the United States	36
POSB187 Study of Awareness of Pharmacy Employees in Ukraine with the Problem of Antibiotics Resistance	36
EE198 Cost-Effectiveness of Sacubitril/Valsartan for the Treatment of Essential Hypertension in Chinese Setting	36
EE332 Cost-Effectiveness Analysis of Using a Smartphone Application to Improve Timely Vaccination Among Children in the Zaatari Refugees Camp, Jordan	35
EE279 A Systematic Literature Review of the Economic Burden in Patients with Myelodysplastic Syndrome	35
CO66 Real-World Study on Characteristics, Post-Nephrectomy Journey, and Outcomes of Patients with Early-Stage Renal Cell Carcinoma Based on Risk Groups	35
PCR71 Health State Utilities in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib or Sunitinib	35
MSR33 Application and Feasibility of Indirect Treatment Comparison of Switch Maintenance and Non-Maintenance Oncology Regimens to Inform HTA Decision-Making	33
MSR40 A Comparison of the Performance of a Range of Trial-Level Surrogacy Methods	33
PCR101 Item Response Theory Analysis of the Ilqi	31
MSR71 Performance of AIC and BIC for the Extrapolation of Survival Data With Different Levels of Censoring	30
POSB231 How to Determine Surgical Pathway Operating Costs in Chronic Rhinosinusitis with Nasal Polyposis Patients? The Time Driven Activity-Based Costing Experiment	30
POSB225 Differences and Similarities in the Methods: of Pricing of Prescription Drugs in Bulgaria, France, Germany, Belgium, and the UK: A Comparative Analysis	30
HTA188 Does Size Matter? Impact of Population Size on Evidence Quality and Negotiation Outcome for Orphan Drugs in Germany	30
EE508 Work Productivity Loss Among Women With Menopausal Symptoms: A Systematic Literature Review	30
RWD120 Impact of Healthcare Fragmentation on Survival of Patients with Colorectal Cancer in Colombia	29
PCR128 Rapid Review: Were There Any Clinical Trials in Non-Muscle Invasive Bladder Cancer That Naturally Adopted the Updated FDA COA Oncology Guidance?	29
PCR100 Development and Validation of Patient-Reported Outcome Measures for Platysma Prominence	29
RWD142 Clinical Characteristics of Chinese Patients with Psoriasis Receiving Interleukin-17A Inhibitors: A Single-Center Retrospective Analysis	28
HTA98 Distribution of the Positive Added Medical Benefit According to the Early Access Status and the Potential Public Health Interest– Analysis of the French HTA Body Opinions (HAS Transparency Commi	28
RWD140 Using Machine Learning to Identify Non-Metastatic Castration-Resistant Prostate Cancer (NMCRPC) Patients from Electronic Health Record Data	28
MT28 A Systematic Literature Review of the Burden Associated with Insertion of Non-Tunneled Central Venous Catheters and the Effectiveness of Ultrasound-Guided Insertion	28
EE23 Economic Impact of Discontinuation and Relapse Rates Among Patients with Schizophrenia Newly Initiated on Lybalvi Versus Olanzapine during First Year Use	28
HTA154 Comparing Non-Oncological Rare Condition Submissions to the National Institute for Health and Care Excellence (NICE) Versus Scottish Medicines Consortium (SMC) From 2001 to 2021	27
HTA18 An Assessment of the Evolving Methods and Role of Health Equity Factors in ICER’s Final Evidence Reports	27
EE301 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) As First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma (La/mUC) in France	27
EE278 Resource Utilization and Caring Cost of People Living With Human Immunodeficiency Virus (PLHIV) in Saudi Arabia: A Tertiary Care University Hospital Experience	27
EE395 Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis in Preterm Infants 29-35 Weeks' Gestation	25
PCR222 The Value of No Cancer Signal Detected Results from Multi-Cancer Early Detection Tests–Perspectives of People in the General Population	25
PCR151 A Patient-Focused Approach to Understand Unmet Needs in Non-Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)	25
HTA9 Evidence Generation Strategy and Insights for Rare Diseases: Case Studies of Mistakes Identified By NICE in Highly Specialized Technology (HST) Assessments	25
POSC246 The Supply Chain of CAR T Cell Therapy: A Systematic Literature Review	25
PCR243 Exploring Health Outcomes By Occupation: Using the National Health and Wellness Survey to Describe Differences in Self-Reported Occupation Profiles	24
SA40 Indexing Regulatory Documents and Clinical Evidence Publications for Non-Small Cell Lung Cancer (NSCLC) Therapeutics: Establishing a Dataset to Enable the Study of Endpoint Fidelity	24
HTA184 Investigating How Orphan Drug Manufacturers Can Optimize Clinical Trial Design so Patients across Geographies Can Access Life-Saving Innovations	24
EE315 Economic Evaluation of Neutralising Monoclonal Antibodies for the Treatment of COVID-19 Positive People in the Community	23
PCR102 Leveraging Social Media for Patient Experience Insights in Rare Disease	23
EE303 Estimating Recurrences Prevented and Costs Avoided with Atezolizumab in Early Non-Small Cell Lung Cancer in the United States	23
EE308 Real-World Treatment Patterns and Costs in Relapsed and Refractory Diffuse Large B-Cell Lymphoma in the United States	23
EE438 Assessing the Budget Impact of Automated Diabetic Retinopathy Screening: A Budget Impact Analysis in Germany	23
PCR39 Preferences and Willingness to Pay of Medication for Patients with Renal Cell Carcinoma in China: A Discrete-Choice Experiment	23
HTA51 Impact of ICER Assessments on Payer Decision Making in the United States	23
SA11 Data Visualization: A Tool to Enhance the Interpretability of Complex and Dense Data Sources	22
CO18 Reuse of Tumor Necrosis Factor Inhibitors for Treatment of Rheumatoid Arthritis Despite Discordance with Patient-Important Outcomes and Standard Disease Assessments	22
RWD38 Quality of Electronic Health Records: Managing Aggregated Patient Demographic Information	22
EE637 Cost of Follow-Up in Patients With Heterozygous Familial Hypercholesterolemia in Spain: Results From the Reality Study	22
EE29 Cost-Effectiveness Analysis and Budgetary Impact of Telescopic Rods for Treatment of Fractures and Correction of Bone Deformities in Children with Osteogenesis Imperfecta in the Brazilian Public	22
RWD53 Assessing the Association of Various Characteristics with Perceived Health Status Among Adults with Skin Cancer in the United States	22
EE406 Households Direct Economic Burden Associated with Chronic Non-Communicable Diseases in Saudi Arabia	21
POSB170 Economic Burden of Depression with Concurrent Anxiety in a General Population of US Adults Based on National Health and Wellness Survey (NHWS)	21

CO109 Patient-Reported Improvements in “Off”-Time Quality, Non-Motor Fluctuation Severity, and Medication Satisfaction in the Real-World Opti-on Study of Opicapone in Parkinson’s Disease	21
POSC238 Real World Data of Acute Pain Prescription in a Health District	21
EE506 Budget Impact Analysis of Dapagliflozin in the Treatment of Chronic Kidney Disease in Mexico	21
PCR153 Navigating Barriers to Patient Participation in Qualitative Interviews from International Clinical Trials in Biliary Tract Cancer (BTC)	21
EE31 Identifying Equity-Relevant Subgroup Effects in Alzheimer’s Disease: A Literature Review to Support a Distributional Cost-Effectiveness Analysis	21
MT36 Use of Mobile Health (MHEALTH) Applications in Cancer: A Trend Analysis	20
EE476 Budget Impact Analysis of iGlarLixi for Treatment of T2DM in Algerian Setting	20
EE561 Estimation of the Economic Burden of Renal Complications of Diabetes in Algeria	19
RWD55 Predicting Metastatic Disease Progression in Prostate Cancer Patients Using Machine Learning of PSA Kinetics	19
MSR110 A Comparison of Stan Versus WinBUGS Software for Conducting Bayesian Hazard Ratio-Based Network Meta-Analysis	19
RWD118 Rapid Diversification of Immune Checkpoint Inhibitor Usage in Community Health Systems in the US Following New Drug Approvals	19
EE429 Cost-Effectiveness and Budget Impact Analyses of Enzalutamide for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer in Mexico	19
RWD86 Healthcare Resource Utilization and Economic Burden of Patients with Gout in the United States	18
OP14 Racial and Ethnic Minority Inclusion in Clinical Outcome Assessment (COA) Research: A Reflection on Current Practices	18
PCR169 A Systematic Literature Review (SLR) of Health State Utility Values (HSUV) in Metastatic Castration-Resistant Prostate Cancer (MCRPC)	18
EE667 The Opportunity of High-Dose Vaccination Against Influenza for Adults Aged 60 and Above in the Netherlands	18
PCR87 Impact of Signs and Symptoms of Chronic Refractory Gout on Patient Health-Related Quality of Life	18
PCR137 A Psycho-Onco Emotional Anxiety (POEM) Framework and Application to Understanding Emotional and Psychological Burden of Living with Cancer	18
EPH96 Risk Factors for Below-the-Knee Amputation in Japanese Patients With Critical Limb Ischemia Who Underwent Plain Old Balloon Angioplasty Therapy: A Claims Database Analysis	18
EE156 Budget Impact Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia in Colombia	18
HSD97 Treatment Utilization and Key Characteristics of COVID-19 Patients Treated with Monoclonal Antibody Therapy in the Outpatient Setting	17
PCR150 Physicians’ Perceptions of the Impact of COVID-19 on Patient Access and Adherence	17
EE151 Cost-Minimization of Lorlatinib Versus Alectinib for First Line Treatment for Treatment of Alk-Positive Non–Small-Cell Lung Cancer from the Brazilian Private Healthcare System Perspective	17
PCR75 Comparing Choice Share Prediction Methods for Discrete Choice Experiments: A Case Study With Hypomethylating Agents in Myelodysplastic Syndromes	17
PCR169 Patient Involvement in Regulatory and HTA Processess: A Call for Enhanced Alignment	17
EPH82 Pharmacotherapy of Obesity in the Russian Federation: Pharmacoepidemiological Study	17
EE172 The Wisdom Self-Management Intervention: A Cost-Effectiveness Analysis to Support the Transformation of Type 2 Diabetes Care in England	16
PRO27 Budget IMPACT Analysis of Pegvisomant in the Treatment Acromegaly in Colombia	16
HSD62 An Analysis of the Status of Newborn Screening Programmes in the European Union and Its Upcoming Developments: What Does This Mean for New Drugs?	16
EE467 Recovid Study. Cost-Effectivness Analysis of Using Nutridrink 200 ML in the Treatment of COVID-19 in the Hospital	16
PCV58 Transcatheter Aortic Valve Implantation VS. Surgical Aortic Valve Replacement for Aortic Stenosis in Taiwan: A Population-Based Cohort Study	16
CO55 Radiographic Progression-Free Survival (RPFS) as a Surrogate Endpoint for Overall Survival (OS) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (MCRPC): A Correlation Meta-A	16
HSD79 Physicians’ Experience and Perceptions of Tetrabenazine for the Treatment of Tardive Dyskinesia	16
HTA48 Minimum Follow-up Time Required for the Detection of the Impact of Treatments on Neuropathic Pain and Gastrointestinal Complaints in Fabry Disease	16
EE190 Association of Total Annual Costs of Duchenne Muscular Dystrophy With Disease Severity	16
HTA49 Determining Appropriate Health Economic Modeling Approaches in Fabry Disease	16
POSB368 Understanding the Impact of Atopic Dermatitis in Portuguese Patients: Results from an Analytical Observational Study	16
CO52 Impact of Digital Interventions on Maintenance Treatment Adherence in Asthma: A Systematic Literature Review (SLR) and Meta-Analysis	16
POSC328 Impact of Treatment Schedule on Adherence and Persistence in Osteoporosis Patients Receiving Long-Acting Therapeutics	16
RWD141 Exploration of Melanoma Patient-Generated Real-World Data Using an Ai-Based Social Listening Approach	16
HSD53 Analysis of the Balanced Scorecard's Internal Subdimensions in Health Care Organizations During the COVID-19 Pandemic	16
EPH65 Assessment of Enzyme Preparations Consumption in Ukraine in Comparison With Other Countries of the World	16
HTA196 Influence of REvalMED Pilot Program on Drug Evaluations in Spain: An Analysis of Therapeutic Positioning Reports	16
HTA70 Forecasting Drug Price for Reimbursement By Utilizing a Value-Price Relationship, a Case Study in Hormone-Relapsed Prostate Cancer	16
PCV53 Trends in Prescription of P2Y12 Inhibitors Following Revascularization in Coronary Heart Disease	16
PDB21 Budget IMPACT Analysis of a Flash Glycose Monitoring Technology in Greece	16
RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US	16
PRO50 A Discrete Choice Experiment to Derive Health State Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency in France	16
MSR15 Psychometric Validation of the Electronic Hidradenitis Suppurativa (HS) Symptom Daily Diary (eHSSDD) and Electronic HS Symptom Questionnaire (eHSSQ) Using Data from the Phase 3 BE HEARD Trials o	15
RWD48 Inpatient Resource Utilization Outcomes Among Patients Living with Fragile X Syndrome and Comorbid Autism Spectrum Disorder in the US	15
EE498 Economic Burden of Interstitial Lung Disease in a Commercially Insured Population with Sjogren's Syndrome in the United States	15
EE302 Households Out-of-Pocket Healthcare Expenditures Based on Number of Chronic Conditions in Riyadh, Saudi Arabia: A Quantile Regression Approach	15
POSB240 The Effects of COVID-19 Infection on Medication Adherence with Chronic Therapies in Italy: The Fail-to-Refill Project	15
MSR23 A Machine Learning Approach to Score Employer Groups Based on How Well They Manage Their Specialty Drug Spend	15
EE375 Cost-Effectiveness Analysis of the Oncotype DX® Test to Reduce Under-Treatment in Patients With HR+/HER2- Node Negative Early-Stage Breast Cancer and Grade 2 T1C Tumours	15
POSC346 Quality of Life of Breast Cancer Patients Treated in a University Hospital in Alexandria, Egypt	15
EE459 Early Intensification of Oral Semaglutide in the UK: A Cost-Effectiveness Analysis Versus Continuing Metformin and SGLT-2 Inhibitor Therapy	14
EPH177 Assessing Student Pharmacists’ Knowledge and Perceptions of Electronic Nicotine Delivery Systems (ENDS) – A Cross Sectional Study at One College of Pharmacy	14
EPH142 The Burden of Metastatic or Inoperable HER2+ Breast Cancer on the Italian Health System	14
EPH168 Assessment of the Prevalence of Emotional Burnout Among Medical Workers in the Republic of Kazakhstan	14
RWD116 Reduced Lysosomal Acid Lipase Activity in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Current Evidence and Future Directions	14
EE402 Social and Economic Burden of Breast Cancer in Russia	14
PCR127 Eliciting Patient Experience for Value Assessment in a Case Study of Spinal Muscular Atrophy	14
PCN75 Cost-Minimization and Budget Impact Analysis of Venetoclax plus Obinutuzumab versus Ibrutinib in High-Risk Patients with Untreated Chronic Lymphocytic Leukemia in the Brazilian Unified Health Sy	13
EE340 Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation in a Developing Country	13
PCR195 Developing a Framework to Capture Economic Impacts on Patients and Caregivers: Recommendations to Guide Patient-Centered Outcomes Research and Value Assessment	13
EPH90 Incidence Rate of Infections and Association between Lupus Nephritis and Serious Infections in Patients with Systemic Lupus Erythematosus: Systematic Literature Review and Meta-Analyses	13
EE359 Cost-Utility of Bictegravir/Tenofovir Alafenamide/Emtricitabine in Naive Patients over 18 Years of Age Living with Human Immunodeficiency Virus Type 1 Infection, from the Colombian’s Health Syst	13
EPH198 Assessing the Validity of Netherlands Linked Routine Healthcare Resource Utilisation Data in the Investigation of Single-Inhaler Triple Therapy Effectiveness (INTREPID Trial)	13
PCN89 Estimating the costs of the management of non-Hodgkin’s lymphoma at a tertiary health institution	13
HPR17 Changing Landscape of Orphan Drug Reimbursement - Evidence From EU-4 and England	13
EPH66 Epidemiological Population Study of Sars-Cov-2 in Lake County, Illinois: Contact: Health-Related Quality of Life Assessment	13
EPH48 Evolution of Polypharmacy and Prescribed Drug Expenditure: The Case of an Insured Poor Population in the Colombian Caribbean during 2018-2021	13
EE220 12-Month Mortality and Healthcare Utilization in a Real-World Patient Population with Severe Tricuspid Regurgitation	13
PCR238 Oral Nutritional Supplementation in Pediatric Patients Diagnosed With Leukaemia Undergoing Chemotherapy: A Review of the Literature	13
EE321 Cost Impact of Next Generation Sequencing Testing in NSCLC with and without RNA Sequencing	13
CO165 Comparison of Non-Robotic Surgery Vs. Robot-Assisted Surgery for Radical Prostatectomy	13
EE565 Health Economic Evaluations on Dengue Vaccine in Indonesia	13
EE549 Burden of Disease of Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D) Using the Standard of Care in Peru	13
SA29 “Cash or Credit?” Feedback from Patients on the Use of Reward Programs in Digital Research	13

EE554 Budget Impact Analysis of Intravenous Acetaminophen in Neonates after Esophageal Atresia and Tracheoesophageal Fistula Repair	12
EE372 Descriptive Analysis of Botulinum Toxin Use for Migraine and Member Costs in an Employed Population	12
EPH62 Annual Burden of Non-COVID-19 Respiratory Tract Infections in the Pre- to Post- Pandemic Eras: Analysis from the Anlitiks’ All Payor Claims Database	12
POSA353 Conceptual Models of the Patient Experience of Duchenne Muscular Dystrophy Constructed from a Qualitative Interview Study with Caregivers	12
EE442 Direct Expenses Study of Liver Transplantation Treatment	12
EE558 Key Methodological Considerations for Developing Cost-Offset Budget Impact Models for a Range of Medical Technologies and Cost Perspectives in Ophthalmology	12
PCR205 Assessment of Healthcare Resource Utilization in Patients with Exocrine Pancreatic Insufficiency in the Pact-CP Registry	12
EE453 Baseline Cognitive Performance Is a Determinant of Prospective Health Resource Utilization Among Adults with Chronic Stroke: A Secondary Analysis	12
PCN190 Budget Impact of the DiviTum®Tka Assay in Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer	12
EPH183 Impact of a Cancer Diagnosis on Non-Cancer Chronic Disease Medication Adherence - A Systematic Literature Review	12
PCR216 Insights from Social Media Posts on the Lived Experience of Alzheimer's Disease	12
P12 Are Gains in Health Utility Associated with Gains in Work Productivity and Role Functioning in Chronic Diseases? A Systematic Literature Review	12
P24 Telehealth Access and Use by the U.S. Medicare Population during the Pandemic	12
POSB336 Comparative Study of Movement Patterns and Development During a 6-Week Training Programme for Triathletes and Orienteerers	11
PCN222 Health Related Quality of Life (HRQoL) Review in Patients with Ovarian Cancer: A Systematic Literature Review (SLR)	11
POSC322 The Impact of Treatment Coefficient Parameterization for Mixture Cure Models on Cost-Effectiveness Models	11
PNS1 Display of Japanese Language Features within Ecoa Measures: Challenges and Recommendations	11
PIN50 Leveraging Publicly Available Data to Estimate a Real-Time Reproduction Number (Rt) for Covid-19: A Comparison of Two Methods	11
POSB333 The Impact of Corrective Training on the Dynamic Axial Deviation of the Lower Limb Among Female Handball Players	11
POSA373 Evaluation of Ehealth Literacy Measurement Tools and Its Associated Factors: A Systematic Review and Meta-Analysis	11
CO87 Treatment Patterns and Costs Associated with Small Cell Lung Cancer in a U.S. Medicare Population	11
MT4 Safety Warnings about Power Morcellation in Hysterectomy: A Simulation of National Impact	11
POSA368 Real-World Dietary Data Collection: Current Challenges and Opportunities for Innovation	11
HPR154 Appropriate Use of Anti-PD(L)1 in Paris Public Hospitals (AP-HP): Are the Prescriptions in Compliance with Reimbursed Indications?	11
P60 A New Online Tool for Valuing Health States: Eliciting Personal Utility Functions for the EQ-5D-5L	11
POSB314 Method of Predicting Serotype Specific Effectiveness Against Invasive Pneumococcal Disease for Pneumococcal Conjugate Vaccines in Infant Population	11
PIN62 Recognising the broader value of vaccines in HTA: ready for prime time?	11
HPR133 Impact of International Reference Pricing (IRP) on Medicines Reimbursement Prices in Bosnia and Herzegovina	11
POSA371 Barriers and Expectations for Patients in Post-Osteoporotic Fractures Care in France: The Effel Study	11
PIN75 Women's Perspectives of Long-Acting Injectable Antiretroviral Therapy in US HIV Healthcare Settings from the CUSTOMIZE Study	11
POSB23 Tafasitamab Plus Lenalidomide (T-L) Versus Standard of Care (SoC) Including 3 Rituximab-Based Treatments or Lenalidomide Monotherapy in Patients with Non-Transplant Eligible Relapsed or Refract	10
MSR45 Smooth Algorithm: An Automatic Method to Estimate the Most Likely Drug Combination in Electronic Health Records. Development and Validation Study	10
HPR102 Exploring the Cost of Managing Diabetes in Nepal: A Cross-Sectional Analysis of Oral Hypoglycemic Medications	10
HSD101 Lack of concordance between real-world treatment patterns and clinical guideline recommendations for metastatic hormone-sensitive prostate cancer (mhspc) patients	10
POSB102 Systematic Literature Review on Cost-Effectiveness and Budget Impact Analysis of Robotic-Assisted Hysterectomy (RAH) for Benign and Malignant Gynecological Conditions	10
HPR45 Analysis of Alternative Access Routes and Time to Access for Paediatric Indication Expansions with Consideration of Regulatory, Pricing, and Access Incentives	10
EE139 Using a User-Friendly Modeling Tool to Inform and Guide Local Decision-Making for Lynch Syndrome Screening at Healthcare Systems	10
POSC161 Cost-Consequence Analysis of Rosuvastatin Versus Atorvastatin in the Spanish Setting	10
EPH23 Sociodemographic and Clinical Characteristics of Patients with Atopic Dermatitis in Colombia:Preliminary Results of Rendac	10
POSC389 Characterisation of Existing Treatment Patterns in Muscle-Invasive Urothelial Carcinoma (MIUC) Across North America, Europe, and East Asia	10
HSD5 Changes in COVID-19 Treatment Patterns over the Course of 2020	10
HPR24 Characteristics, Healthcare Resource Utilization, Cost, and Quality Outcomes of Medicare Beneficiaries While Commercially Insured and after Transition to Medicare Advantage Versus Traditional Fe	10
EE133 Budget Impact Related to Complications on Post-Bariatric Surgery Patients in Brazilian Public Healthcare System	10
PNS51 Global Survey of Genetic Testing Reimbursement Policies	10
MSR30 Modelling Monthly Migraine Day Distribution: A Case Study of Fremanezumab Japanese-Korean Clinical Trials for Migraine Prevention	10
EE154 Burden of Invasive Extraintestinal Pathogenic E. coli Disease Among Older Adult Patients Treated in Hospitals in the US	10
CO107 Clinical Outcomes of Patients With Metastatic Renal Cell Carcinoma (MRCC) With or Without Sarcomatoid Differentiation Treated With Systemic Therapy in Real-World Canadian Setting	10
POSC17 A TARGETED LITERATURE REVIEW TO COMPARE COVID-19 SYMPTOM DIARIES AND PATIENT-REPORTED CONCEPT	10
HPR43 The Influence and Implementation of Pathways of Care for Hematologists Compared to Oncologists in the United States	10
HSD129 Managing Members with Complex Conditions: A Blue Cross and Blue Shield of Louisiana Program Evaluation	10
EE209 Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment in Adult Patients Following Complete Resection and Platinum-Based Chemotherapy with Non-Small Cell Lung Cancer (NSCLC) in Finlan	10
EE214 Modelling Cost Determinants for Treating Metastatic Castration-Resistant Prostate Cancer: An Italian National Healthcare System's Perspective Cost Analysis	10
HTA72 Survival Extrapolation for Immuno-Oncology Drugs: Pessimism or Optimism? a Targeted Literature Review and a Validation-Based Case Study	10
CO83 Reduction of Transfusion Requirements and Length of Hospital Stay in Patients Undergoing Major Planned Surgery After the Implementation of Patient Blood Management (PBM) in Spain	10
PMH15 Budget IMPACT Analysis of Lurasidone VS Other Atypical Antipsychotics in Patients with Schizophrenia in China	9
EPH158 Years of Life Lost Due to Diabetes Mellitus in Colombia, 1979-2017	9
EE15 Cost-Consequence Analysis of Ofatumumab in Comparison With Other Disease-Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada	9
HPR59 Targeted and Immunotherapies for Cancer - Reimbursement and Expenditure in a Single-Payer Healthcare System in Bulgaria	9
PMS21 Change and Opportunity: U.S. Community Rheumatologists' Perceptions of and Plans to Address Evolving Industry Dynamics	9
PMH37 Do Education Costs Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector.	9
Research Presentations Financial Disclosure Statements	9
POSA89 Annual Health Insurance Treatment Cost of Non-Insulin-Dependent Diabetes with Peripheral Circulatory Complications Based on Routinely Collected Financing Data	9
EPH69 Cancers Treatment from Their Perspective: A Qualitative Pilot Study Exploring the Knowledge Attitude and Practice of Folk Medicine Practitioners in a Low-and-Middle-Income-Country	9
PMU34 The Influence of Expedited Approval Designations on Health PLAN Coverage: An Empirical Evaluation	9
CO177 Association Between the Sarcomatoid Status and Percentage of Sarcomatoid on the Clinical Outcomes of Localized Renal Cell Carcinoma Post Nephrectomy	9
POSB62 Budget Impact Analysis of Ertugliflozin Inclusion in the List of Vital and Essential Medicines in Russian Federation	9
POSA87 Annual Health Insurance Treatment Cost of Mental and Behavioural Disorders Due to Use of Opioids Based on Routinely Collected Financing Data	9
HPR50 Challenges That EUnetHTA21 Will Have to Address to Make a Success of Joint Clinical Assessments	9
PIN5 Immunogenicity and Safety of the COVID-19 Vaccines Compared to Controls in Healthy Adults: A Systematic Review	9
EPH67 Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employee "Caregivers” of Patients with Breast, Skin, GI, Female, Male, and "Other” Cancers	9
PMU8 The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases	9
EPH61 Comparing Fibrosis Staging Approaches Among Patients with Non-Alcoholic Steatohepatitis (NASH) Using Real World Data (RWD)	9
EPH139 COVID-19 Vaccine Related Adverse Events in a Population Aged 5–17 Years: A Study of Reports from the VAERS Database	9
POSB55 Economic Consequences of Anti-HCV Treatment of Patients Diagnosed through Screening in Italy: A Prospective Modelling Analysis	9
POSA158 Actualization of the Budget Impact Scale for HTA Guideline in Ukraine	9
P32 Power Implications of Estimator Choice in Synthetic Control Arm Analyses: Results from a Simulation Comparing Average Treatment Effects on the Treated and Untreated Under Propensity Score Weightin	9
POSA109 The Impact of Improving the Current Approach to Chronic Obstructive Pulmonary Disease Within the Spanish National Health System: A Social Return on Investment Analysis	9
PMH33 Cost-Utility Analysis of Lurasidone for the Treatment of Schizophrenia in China	9
POSC405 Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers' Compensation for Employees with Musculoskeletal Conditions in the United States	9
SA48 Methods to Account for the Impact of COVID-19 in Real-World Retrospective Studies of Economic Outcomes: A Targeted Literature Review	8
HSD16 Trends in Rheumatology Patient Care and Practice Operations Pre- and Post-COVID-19 Pandemic	8
CO210 An Updated Systematic Review and Network Meta-Analysis on Risks of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis	8
EE481 Long-Term Cost-Effectiveness of Tirzepatide Versus Placebo for Individuals With Type 2 Diabetes and Obesity	8
PCR207 Health-Related Quality of Life and Its Associate Factors Among Residents in Tianjin, China: Findings from 2023 National Health Service Survey	8
PSY4 Budget Impact of Baricitinib for Moderate-to-Severe Atopic Dermatitis Patients with an Inadequate Response to Topical Treatments	8
EE128 Facing the Challenge of Ageing: Cost-Effectiveness of the SPRINT-T Protocol	8
RWD99 The Financial Burden of DM on the Public Health System of Greece: Using Big Data From Greece	8
POSC138 The Burden Due to Moderate-to-Severe Paediatric Atopic Dermatitis Treated with Systemic Immunosuppressants on the Healthcare System in England	8
PT4 Will the IRA's Negotiation Timelines Delay Access to Drugs for Orphan Indications?	8
PCR222 Comparison of Recanalisation Therapies in Terms of Quality of Life in Ischaemic Stroke Patients in Hungary	8
EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study	8
PCN36 Oncology Combinations: How to Ensure Timely Access?	8
Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification	8
EPH222 Trends of Mortality Related With Dengue in Colombia 2012-2021	8
Editorial Board	8